Search Results - "Catalano, R. B."

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer by Treat, J.A., Gonin, R., Socinski, M.A., Edelman, M.J., Catalano, R.B., Marinucci, D.M., Ansari, R., Gillenwater, H.H., Rowland, K.M., Comis, R.L., Obasaju, C.K., Belani, C.P.

“…Paclitaxel–carboplatin is used as the standard regimen for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This trial was designed to…”
Get full text

Phase I trial of recombinant macrophage colony-stimulating factor and recombinant γ-interferon : toxicity, monocytosis, and clinical effects by WEINER, L. M, WEI LI, HOLMES, M, CATALANO, R. B, DOVNARSKY, M, PADAVIC, K, ALPAUGH, R. K

“…Macrophage colony-stimulating factor (M-CSF) is a known inducer of proliferation and differentiation of cells of the mononuclear phagocyte lineage, and…”
Get full text

Control of common physical symptoms other than pain in patients with terminal disease by Levy, M H, Catalano, R B

Get more information

Phase II study of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy by Creech, R H, Shah, M K, Catalano, R B, Dierks, K, Dayal, H, Goldberg-Alberts, R

“…Forty-three evaluable patients with ovarian cancer who had failed one or more chemotherapy regimens were treated with mitomycin iv at 28-day intervals…”
Get more information

Phase II study of 5-day infusion of vinblastine in patients with advanced ovarian carcinoma by Shah, M K, St Marie, K, Catalano, R B, Dierks, K, Creech, R H

Get more information

Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer by Creech, R H, Catalano, R B, Dierks, K M, Shah, M K

“…Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at…”
Get more information

Effective control of cisplatin-induced nausea using high-dose steroids and droperidol by Mason, B A, Dambra, J, Grossman, B, Catalano, R B

“…Seventy-three consecutive patients receiving cisplatin-containing chemotherapy regimens were treated with an initial dose of chlorpromazine (25 mg im),…”
Get more information

A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma by Bellet, R E, Catalano, R B, Danna, V G, Berd, D A, Berkelhammer, J, Mastrangelo, M J

Get more information

The Coalition of cancer cooperative groups GI scientific leadership council by Catalano, R. B., Comis, R. L., O’Connell, M. J.

“…Abstract only 13522 Background: The Coalition of Cancer Cooperative Groups convened the GI Scientific Leadership Council (GI SLC) to provide leadership in…”
Get full text

Upper hemibody and local chest irradiation as consolidation following response to high-dose induction chemotherapy for small cell bronchogenic carcinoma--a pilot study by Mason, B A, Richter, M P, Catalano, R B, Creech, R B

“…Encouraging results of the combination of upper hemibody irradiation (UHBI) and local chest irradiation (LCI) combined withh standard-dose chemotherapy in…”
Get more information

Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea by BENSON, Al B, AJANI, Jaffer A, WADLER, Scott, CATALANO, Robert B, ENGELKING, Constance, KORNBLAU, Steven M, MARTENSON, James A, MCCALLUM, Richard, MITCHELL, Edith P, O'DORISIO, Thomas M, VOKES, Everett E

“…To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. An expert multidisciplinary…”
Get full text

Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea by Bellet, R E, Catalano, R B, Mastrangelo, M J, Berd, D

“…Twenty-five patients with measurable metastatic melanoma refractory to DTIC and a nitrosourea were treated with dibromodulcitol (DBD). DBD was administered…”
Get more information

Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma by Paul, A R, Catalano, R B, Engstrom, P F

“…Thirty-seven previously untreated patients with advanced metastatic colorectal carcinoma were treated in a prospective randomized fashion with either ICRF-159…”
Get more information

Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma by Bellet, R E, Catalano, R B, Mastrangelo, M J, Berd, D

“…Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC-45388) and a nitrosourea were treated with 5-azacytidine (NSC-102816)…”
Get more information

Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy by Shah, M K, Engstrom, P F, Catalano, R B, Paul, A R, Bellet, R E, Creech, R H

Get more information

Phase II study of ICRF-159 in refractory metastatic breast cancer by Creech, R H, Engstrom, P F, Harris, D T, Catalano, R B, Bellet, R E

“…ICRF-159, at a dose of 300 mg/m2, was given orally every 8 hours for nine doses every 21 days to 40 patients with metastatic breast cancer refractory to…”
Get more information

Expanding participation to non-group members in phase III cooperative group treatment trials by Denicoff, A. M., Hopkins, J. R., Riordan, S. E., Adler, J. M., Marinucci, D. M., Geisen, K., Lambersky, R., Catalano, R. B., Mooney, M. M., Abrams, J. S.

“…Abstract only 6533 Background: The NCI initiated the Cancer Trials Support Unit (CTSU) Independent Clinical Research Site (CICRS) Program at the ASCO Annual…”
Get full text

Minority patients in clinical trials (CT) for advanced non-small cell lung cancer by Obasaju, C. K., Catalano, R. B., Marinucci, D. M., Bloss, J. D., Taylor, L., Monberg, M. J., Comis, R. L.

“…Abstract only…”
Get full text

An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients by Creech, R H, Catalano, R B, Shah, M K

“…Sixty breast cancer patients with hormone-resistant metastatic disease who had progressed after chemotherapy with low-dose cyclophosphamide, methotrexate, and…”
Get more information

A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L) by Treat, J., Belani, C. P., Edelman, M. J., Socinski, M. A., Ansari, R. H., Obasaju, C. K., Bloss, J. D., Marinucci, D. M., Catalano, R. B., Comis, R. L.

“…Abstract only…”
Get full text